Rivogenlecleucel not checked
Bellicum Pharmaceuticals · BPX-501 T cells · BPX-501
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.”In the company’s words, NCT01744223 on ClinicalTrials.gov
- Tested for
- Myelodysplastic Syndromes (3 trials), Acute Lymphoblastic Leukemia (2 trials), Lymphoma (2 trials), Acute Myelogenous Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Primary Immune Deficiency Disorder, Osteopetrosis and 7 more
- Main trialPhase 1/2
- “This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the laboratory and then given back to the patient along with the stem cell transplant (T cell addback), can help the immune system recover faster after the transplant. As a safety measure, these T cells have been "programmed" with a "self-destruct switch" so that if, after they have been given to the…”In the company’s words, NCT01744223 on ClinicalTrials.gov
- Other names
- BPX-501 T cells · BPX-501
Other drugs for Myelodysplastic Syndromes
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
- MomelotinibSierra Oncology LLC - a GSK company · Phase 2/3
- VenetoclaxAbbVie · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 9 Oct 2019 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | |
| Phase 1/2Active, not recruiting | 11 May 2021 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | |
| Phase 1Active, not recruiting | 14 Jan 2020 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | |
| Phase 1Active, not recruiting | Sep 2022 | Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant | |
| Phase 2/3Terminated | 23 Jul 2019 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS | |
| Phase 1/2Terminated | 30 Jun 2020 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | |
| Phase 1/2Terminated | Jun 2020 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | |
| Phase 1Terminated | Sep 2015 | Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026